Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1995-04-07
1997-04-22
Dees, Jos e G.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514561, A61K 31195, A61K 3142
Patent
active
056229810
ABSTRACT:
A method of treating a mammal with a neurodegenerative disease which is caused at least in part by the neurotoxic effects of the .beta.-amyloid protein. This method constitutes administering a metabotropic receptor agonist to such a mammal. In particular, the agonist trans-ACPD or 1S,3R-ACPD can be administered intravenously to treat a mammal with Alzheimer's disease.
REFERENCES:
patent: 5028622 (1991-07-01), Plaitakis
patent: 5135956 (1992-08-01), Borg et al.
patent: 5158976 (1992-10-01), Rosenberg
Abstract, ".beta.-Amyloid Peptide Potentiates Quisqualate Toxicity in HT-4 Neuronal Cell Line", Kelleher, Estrada and Eveleth, 24th Annual Meeting for Amer. Soc. for Neurochem., VA, Mar. 1993.
"A Metabotropic Glutamate Receptor Agonist Does Not Mediate Neuronal Degeneration in Cortical Culture", Koh, Palmer, Line and Cotman, Brain Res., 561 (1991) 338-343.
"Acetylcholine and Glutamate Mediate Fast Excitation; GABA and Glycine Mediate Fast Inhibition", Ligand-gated Ion Channels and Fast Synaptic Transmission, Chap. 19, The Nervous System, 1083-1084 no date.
"Learning in the Mammalian Hippocampus Depends on Ca.sup.2+ Entry Through a Doubly Gated Channel", Non-Channel-linked Receptors and Synaptic Modulation, Chap. 19, The Nervous System, 1099-1100, no date.
"62 -Amyloid Increases Neuronal Susceptibility to Injury by Glucose Deprivation", Copani, Koh and Cotman, Neuropharmacology and Neurotoxicology NeuroReport 2, 763-765 (1991).
"Activation of Metabotropic Receptors Has a Neuroprotective Effect in a Rodent Model of Focal Ischaemia", Chiamulera, Alebertini, Valerio and Reggiani, European J. of Pharmacology, 216 335-336 (1992).
"Metabotropic Excitatory Amino Acid Receptors Reveal Their True Colors", TiPS, Oct. 1991, vol. 12, 365-367.
".beta.-Amyloid Protein Increases the Vulnerablity of Cultured Cortical Neurons to Excitotoxic Damage", Koh, Yang and Cotman, Brain Research, 533 (1990), 315-320.
"Activation of the Metabotropic Glutamate Receptor Attenuates N-Methyl-D-Aspartate Neurotoxicity in Cortical Cultures", Proc. Natl. Acad. Sci. USA, vol. 88, Nov. 1991, Neurobiology, 9431-9435.
Neuroscience Facts, FIDIA Res. Foundation, Sep. 1992, vol. 3, No. 17, 65-68.
"Vintage Amino Acid Meeting Describes New Tools for Amino Acid Research, Subtypes of Metabotropic Receptors", Henley and Johnston, Meeting Rpt., TiPS, vol. 12, Oct. 1991, 357-359.
".beta.-Amyloid Stimulates Glial Cells In Vitro to Produce Growth Factors that Accumulate in Senile Plaques in Alzheimer's Disease", Araujo and Cotman, Brain Research, 569 (1992) 141-145.
"Preservation of 5-Hydroxytryptamine.sub.1A Receptor-G Protein Interactions in the Cerebral Cortex of Patients with Alzheimer's Disease" O'Neill et al., Neuroscience Letters, 133 (1991) 15-19.
"Glutamate Neurotoxicity and Diseases of the Nervous System", Dennis W. Choi, Neuron, vol. 1, Oct. 1988 623-634.
"Systemic Administration of MK-801 Protects Against Ischemia-Induced Hippocampal Neurodegeneration in the Gerbil", Foster and Woodruff, The Journal of Neuroscience, Oct. 1987 3343-3349.
"Pharmacological Protection Against the Toxicity of N-Methyl-D-Aspartate In Immature Rat Cerebellar Slices", A. Lehmann, Neuropharmacology, vol. 26, No. 12, 1751-1761 (1987).
"Blockade of N-Methl-D-Aspartate Receptors May Protect Against Ischemic Damage in the Brain", Science, vol. 226, 850-852 (1984).
"Abusive Stimulation of Excitatory Amino Acid Receptors: A Strategy to Limit Neruotoxicity", Manev et al., The FASEB Journal, vol. 4 Jul. 1990, 2789-2797 no date.
"Glutamate Neurotoxicity Is Independent of Calpain In Inhibition in Primary Cultures of Cerebellar Granule Cells", Manev, et al., Journal of Neurochemistry, vol. 57, No. 4, 1288-1295 1991.
"Desensitization of Metabotropic Glutamate Receptors in Neuronal Cultures", Catania, et al., Journal of Neurochemistry, vol. 56, No. 4 1329-1335 1991.
"Abstract #72" 18th International Joint Conference on Stroke and Cerebral Circulation, p. 179, no date.
Silprandi, Renata, et al. (1992) "Activation of the glutamate metabotropic receptor protects retina against N-methyl-D-aspartate toxicity", European Journal of Pharmacology, 219:173-174.
Dewar, D., et al. (1991) "Glutamate metabotropic and AMPA binding sites are reduced in Alzheimer's disease: an autoradiographic study of the hippocampus", Brain Research, 553:58-64.
Nakamura, Yu, et al., (1992) "Amyloid .beta.-protein precursor deposition in rat hippocampus lesioned by ibotenic acid injection", Neuroscience Letters, 136:95-98.
Baskys, A., (1991) "Agonists at Metabotropic Glutamate Receptors Presynaptically Inhibit EPSC's In Neonatal Rat Hippocampus", Journal of Physiology, 444:687-701.
The Merck Index (1989), Merck & Co., Rahway, NJ, USA; see page 775, No. 4808: Ibotenic acid.
Cotman Carl W.
Eveleth David D.
Kelleher Judith A.
Bembenick B.
Cortex Pharmaceuticals, Inc.
Dees Jos e G.
LandOfFree
Use of metabotropic receptor agonists in progressive neurodegene does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of metabotropic receptor agonists in progressive neurodegene, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of metabotropic receptor agonists in progressive neurodegene will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-342079